Home sweet parking lot: Some hospitals welcome RV living for patients, families, and workers

FHS
July 27, 2023
10:50 am

Jim Weaver has had two major surgeries in the past decade: one to remove cancerous tumors from his bladder and another to clear a blocked artery.

Apellis expects EU to reject eye drug; Terray teams up with Bristol Myers; Vandria raises $20M

Plus, news on Inductive Bio, AbelZeta Pharma, GPCR Therapeutics, Bridge Biotherapeutics and NextCure. Apellis preempts EU rejection for eye drug: The company expects a negative

December 15, 2023

The Endpoints 11 event is coming: Meet biotech’s hottest new startups

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 6, 2024

CDC: Nirsevimab 90% Effective Against RSV Hospitalization in Infants

Immunizing infants in their first respiratory syncytial virus (RSV) season with nirsevimab (Beyfortus) proved highly protective against severe disease, a case-control study showed. From October

March 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.